Affordable Access

Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol

Authors
  • Mueller, Ruediger B.
  • Spaeth, Michael
  • von Restorff, Cord
  • Ackermann, Christoph
  • Schulze-Koops, Hendrik
  • von Kempis, Johannes
Publication Date
Mar 03, 2019
Source
MDPI
Keywords
Language
English
License
Green
External links

Abstract

fixed regimen n = 55). Conclusion: Treat-to-target management with the optimization of csDMARDs, oral, and IA-GCs of RA patients in parallel to a newly established CZP treatment was safe and efficacious in comparison to a fixed regimen of csDMARDs background therapy.

Report this publication

Statistics

Seen <100 times